It is known that tumor stem cells share many properties with non-malignant stem cells, such as expression of CD133. The receptor for stem cell factor, c-kit, is found on numerous types of normal stem cells in addition to hematopoietic stem cells, where it was originally discovered.
This current patent discloses a variety of compounds that inhibit activity of the c-kit kinase. The compounds are indolinone derivatives and are claimed for activity against gastrointestinal tumors, mastocytomas, allergy-associated chronic rhinitis, inflammation or asthma.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.